See other companies on Welcome to the Jungle
Resilience
Biopharmaceutical manufacturing company
- 1001+ employees
- Healthcare
- B2B
- Supply Chain
- MedTech
- University City, San Diego, CA
Jump to section
Company mission
To broaden access to complex medicines and protect biopharmaceutical supply chains against disruption.
Our take
Resilience (also known as National Resilience) is a first-of-its-kind, technology-focused manufacturing company that has set out to broaden access to complex medicines, while protecting the biopharmaceutical supply chain against disruption. From vaccines, and cell therapy, to nucleic acid, and gene therapy modalities, Resilience is playing a vital part in advancing the biopharmaceutical ecosystem.
The company’s sustainable network of high-tech, end-to-end manufacturing solutions ensures groundbreaking medicines can be developed quickly, safely, and at scale. Founded in 2020, the company has made quick work of growing its influence in the industry, having gone well beyond unicorn status with over $2.5 billion in funding.
The company has focused its efforts on expanding its manufacturing network outside of North America. Fueled by its early 2023 equity investment from Mubadala, Resilience is set to establish a new manufacturing facility in the UAE. The new facility will be the first Good Manufacturing Practice (GMP) biopharma facility in the region based in Abu Dhabi.
Kirsty
Company Specialist at Welcome to the Jungle
Benefits
- Equity
- Annual cash bonus program
- 401(k) plan with a generous company match
- Medical, dental and vision insurance
- Family building benefits
- Tuition reimbursement
- Life and disability insurance
- Flexible time off
- Paid holidays + other paid leaves of absence
- Support for caregiving needs
Company values
- Resilience + Grit - We couple a passion for impact with the perseverance to see them through
- Builder Mentality - We’re creators, inventors, and builders
- Quality + Rigor - Details matter. We dive deep into data, discover patterns, and develop insights
- Velocity - Speed is a virtue. We don’t let the perfect be the enemy of the good
- Service Orientation - We never lose sight of the patients who are the ultimate beneficiaries
- Ownership - We seize the initiative, chafe at the status quo, and always look for a better way
- EQ + IQ - We fuse intellect with effective communication and collaboration
Funding (last 2 of 5 rounds)
Oct 2024
$17.5m
GRANT
Jun 2022
$625m
SERIES D
Total funding: $2.0bn
This company has top investors
Leadership
Rahul Singhvi
(CEO)Former President of Ring Therapeutics, Operating Partner at Flagship Pioneering, and COO at Takeda.
Sandy Mahatme
(President, COO & CFO)Current Board Member at Idorsia Pharmaceuticals. Former Board Member at Idorsia Pharmaceuticals, Aeglea BioTherapeutics, and Flexion. Worked at Sarepta Therapeutics as the CFO & CBO.
Drew Oetting
(Director)Also co-founded Affinity.co., and 8VC. Is currently also a Partner at Formation 8.